Authors
Benjamin Movsas, Jennifer Moughan, Linda Sarna, Corey Langer, Maria Werner-Wasik, Nicos Nicolaou, Ritsuko Komaki, Mitchell Machtay, Todd Wasserman, Deborah Watkins Bruner
Publication date
2009/12/1
Journal
Journal of clinical oncology
Volume
27
Issue
34
Pages
5816-5822
Publisher
American Society of Clinical Oncology
Description
Purpose
To determine the added value of quality of life (QOL) as a prognostic factor for overall survival (OS) in patients with locally advanced non–small-cell lung cancer (NSCLC) treated on Radiation Therapy Oncology Group RTOG-9801.
Patients and Methods
Two hundred forty-three patients with stage II/IIIAB NSCLC received induction paclitaxel and carboplatin (PC) and then concurrent weekly PC and hyperfractionated radiation (to 69.6 Gy). Patients were randomly assigned to amifostine (AM) or no AM during chemoradiotherapy. The following pretreatment factors were analyzed as prognostic factors for OS: Karnofsky performance status, stage, sex, age, race, marital status, histology, tumor location, hemoglobin, tobacco use, treatment arm (AM v no AM) and QOL scores (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 [QLQ-C30] and Lung Cancer 13 [LC-13 …
Total citations
Scholar articles
B Movsas, J Moughan, L Sarna, C Langer… - Journal of clinical oncology, 2009